(Albany, US) DelveInsight launched a new report on Beta-thalassemia Market Insights, Epidemiology and Market Forecast-2030.
DelveInsight’s “Beta-thalassemia (B-thal) – Market Insights, Epidemiology, and Market Forecast-2030“ report delivers an in-depth understanding of the Beta-thalassemia (B-thal), historical and forecasted epidemiology as well as the Beta-thalassemia (B-thal) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the report
1. The total prevalent population of Beta-thalassemia in 6MM was 14,191 in 2017.
2. The total prevalent cases for Beta-thalassemia were highest in Italy, followed by the United States and Germany.
3. Endocrine complications and Osteoporosis was found in the majority of patients with Beta-Thalassemia.
Request for sample pages: https://www.delveinsight.com/sample-request/beta-thalassemia-thal-market
Key benefits of the report:
1. Beta-thalassemia market report covers a descriptive overview and comprehensive insight of the Beta-thalassemia epidemiology and Beta-thalassemia market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Beta-thalassemia market report provides insights into the current and emerging therapies.
3. Beta-thalassemia market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Beta-thalassemia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Beta-thalassemia market.
Beta Thalassemia is a genetic disorder which is inherited in an autosomal, recessive fashion. The clinical manifestations seen in patients are severe anaemia, abnormal haemoglobin and buildup of iron in the body. Being a genetic disorder, there is no specific treatment for Beta Thalassemia and the treatment regimen mainly focus on delaying progression of the disease and relieving the symptoms.
Novartis developed Exjade (Deferasirox), which is an oral iron chelator approved by the US FDA in 2005. It is a member of a new class of tridentate iron chelators, the N-substituted bis-hydroxyphenyl-triazoles. Metabolism and elimination of deferasirox are primarily by glucuronidation followed by hepatobiliary excretion into the faeces. Approved in more than 70 countries including the US and Europe, Exjade is the first once-daily oral iron chelator approved for use in patients with chronic transfusional iron overload who have a wide range of underlying anaemias.
Request for sample pages: https://www.delveinsight.com/sample-request/beta-thalassemia-thal-market
The launch of the emerging therapies is expected to significantly impact the Beta-thalassemia treatment scenario in the upcoming years:-
Drugs covered:
1 LentiGlobin BB305
2 PTG-300
3 ACE-011 (Sotatercept)
4 Mitapivat
5 IONIS TMPRSS6 LRx
6 VIT 2763
7 Emeramide
And many others
The key players in Beta-thalassemia market are:
1. BlueBird Bio
2. Protagonist Therapeutics
3. Acceleron Pharma
4. Celgene Corporation
5. Agios Pharmaceuticals
6. Ionis Pharmaceuticals
7. Vifor Pharma
8. EmeraMed
And many others
Request for sample pages: https://www.delveinsight.com/sample-request/beta-thalassemia-thal-market
Table of contents
1 Key Insights
2 Executive Summary of Beta Thalassemia
3 SWOT Analysis for Beta Thalassemia
4 Beta Thalassemia Market Overview at a Glance
5 Beta-thalassemia Disease Background and Overview
6 Beta-thalassemia Epidemiology and Patient Population
7 Country Wise-Epidemiology of Beta Thalassemia
8 Beta-thalassemia Treatment and Management
9 Case Study
10 Unmet Needs
11 Beta-thalassemia Marketed Products
12 Beta-thalassemia Emerging Therapies
13 Other Promising Candidates
14 Other Products in the News
15 Discontinued Therapies
16 Beta Thalassemia: 6 Major Market Analysis
17 Beta-thalassemia Market Outlook by Country
18 Market Access and Reimbursement Landscape
19 Market Drivers
20 Market Barriers
21 Appendix
22 DelveInsight Capabilities
23 Disclaimer
24 About DelveInsight
Request for Detailed TOC: https://www.delveinsight.com/sample-request/beta-thalassemia-thal-market
Related Reports:
Beta-thalassemia (B-thal) – Epidemiology Forecast to 2030
DelveInsight’s ‘Beta-thalassemia (B-thal) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Beta-thalassemia (B-thal) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/beta-thalassemia-market-forecast?utm_source=Pressrelease&utm_medium=Pressrelease&utm_campaign=Pressrelease